Form 4: Arcutis Biotherapeutics Director Sells Shares
Insider Transaction (Form 4)
Terrie Curran, a Director of Arcutis Biotherapeutics, Inc., sold 1,072 shares of common stock on August 20, 2026 for $26.04 per share.
Summary
- Option exercise/conversion: acquired 1,072 Common Stock at $7.51 ($8,051) on August 20, 2026; holds 24,598 after (Direct).
- Open-market sale: disposed of 1,072 Common Stock at $26.04 ($27,912) on August 20, 2026; holds 23,526 after (Direct).
- Option exercise/conversion: disposed of 1,072 Stock Option (right to buy) on August 20, 2026; holds 11,148 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $27,912 of stock on the open market.
Insider Transactions
Terrie Curran — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Option exercise/conversion | Common Stock | 1,072 | $8 | $8.1K | 24,598 |
| 2026-08-20 | Open-market sale | Common Stock | 1,072 | $26 | $27.9K | 23,526 |
| 2026-08-20 | Option exercise/conversion | Stock Option (right to buy) | 1,072 | — | — | 11,148 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Option exercise/conversion (1,072 shares) |
| 2026-08-20 | Open-market sale (1,072 shares) |
| 2026-08-20 | Option exercise/conversion (1,072 shares) |
Keywords
insider transaction, Form 4, ARQT, Arcutis Biotherapeutics, Inc., bearish, Terrie Curran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.